Printer Friendly

UNIGENE, JOHNS HOPKINS EXPLORE METHODS TO COMBAT CANCER METASTASIS

   UNIGENE, JOHNS HOPKINS EXPLORE METHODS TO COMBAT CANCER METASTASIS
    FAIRFIELD, N.J., Nov. 1 /PRNewswire/ -- Unigene Laboratories, Inc. (NASDAQ: UGNE) today announced the establishment of a research collaboration with the Johns Hopkins School of Medicine to investigate the mechanisms by which cancerous tumors can metastasize, or spread, to different sites in the body.  The objective of the program will be to identify specific proteins on cancer cell surfaces which are involved in metastasis.  Such information could, for the first time, allow doctors to predict accurately the metastatic potential of known tumors and facilitate the development of drugs which can inactivate those proteins and halt the spread of cancer.
    The ability of a tumor to metastasize rapidly is often the single most important factor in determining its lethality.  The prognosis for patients with highly metastatic cancers (e.g. lung, pancreas, esophagus) is particularly poor, and it sharply worsens for every type of cancer once metastasis has occurred.  Often, similar patterns of tumor spread are observed in patients with similar cancers, suggesting that specific rather than random biochemical processes are occurring and that a single, generic approach to halt tumor migration might be effective for most, if not all, cancers.
    The program will focus on a family of so-called "cell adhesion" proteins which are found on the surfaces of certain tumor cells.  These proteins are thought to play a role in enabling cancer cells to gain access to the blood vessel network and establish new tumors at secondary sites in the body.  Other types of cell adhesion proteins on the surfaces of normal cells are being studied in many laboratories as a possible cornerstone of new therapies to treat a wide spectrum of diseases ranging from arthritis to the common cold.
    "We strongly believe that this program represents an important new approach to the study of metastatic cancer," commented Ronald S. Levy, vice president of Unigene.  "The synergies that will result from our involvement with the already active Johns Hopkins research effort will greatly foster the development of a first rate research program in this very promising field."
    In addition to providing funding for the University researchers, Unigene is also assembling its own internal research team.  J. Thomas August, who currently directs the University effort, will be Unigene's consultant for the program and will coordinate the joint activities of the two laboratories.
    Unigene Laboratories, Inc. develops technology and products with applications in the health care field.  Its proprietary amidation process is capable of producing peptide hormones for the treatment of a variety of diseases and disorders including osteoporosis, diabetes and hypertension.
    -0-                11/1/91
    /CONTACT:  Ronald S. Levy, vice president of Unigene Laboratories, 201-882-0860/
    (UGNE) CO:  Unigene Laboratories, Inc.; The Johns Hopkins School of Medicine ST:  New Jersey IN:  MTC SU: SH-OS -- NY056 -- 0317 11/01/91 15:22 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1991
Words:469
Previous Article:GENERON SYSTEMS EXPANDS ITS MEMBRANE MODULE PRODUCTION FACILITY AT DOW CHEMICAL'S PITTSBURG, CALIF. PLANT
Next Article:COOL THINGS TO HAPPEN IN SEATTLE AREA: SWEEPSTAKES OFFERS ROCK & ROLL, FIGHTER JETS AND MORE COOL STUFF
Topics:


Related Articles
INSTITUTIONS TO COLLABORATE ON CANCER-FIGHTING PECTIN
UNIGENE IND ALLOWED BY FDA; PHASE III TRIALS FOR OSTEOPOROSIS PRODUCT TO BEGIN SHORTLY
Unigene Announces Breakthrough in Production of Osteoporosis Drug
Magainin Begins Phase I Human Clinical Testing of Squalamine for Cancer Also Presents Preclinical Data in Breast Cancer
Unigene Receives $3 Million from Warner-Lambert - Achieves Additional Benchmarks In Development Of Oral Osteoporosis Product -.
Unigene Receives Unanimous European Recommendation to Approve Injectable Calcitonin Product for Paget's Disease and Hypercalcemia.
Calydon Announces Issuance of Two Patents for Technologies That Destroy Cancer Tumors, Including Prostate Cancer.
Allos Therapeutics, Inc. Announces RSR13 Phase II Clinical Results to Be Presented in Two Oral Presentations at ASCO.
Unigene Files U.S. New Drug Application for FORTICAL(R), Nasal Calcitonin Product for Osteoporosis; Upsher-Smith Laboratories Inc. to Package, Market...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters